166 related articles for article (PubMed ID: 32700798)
1. In vitro and in vivo human metabolism and pharmacokinetics of S- and R-praziquantel.
Kapungu NN; Li X; Nhachi C; Masimirembwa C; Thelingwani RS
Pharmacol Res Perspect; 2020 Aug; 8(4):e00618. PubMed ID: 32700798
[TBL] [Abstract][Full Text] [Related]
2. Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450-Mediated Drug-Drug Interaction.
Vendrell-Navarro G; Scheible H; Lignet F; Burt H; Luepfert C; Marx A; Abla N; Swart P; Perrin D
Drug Metab Dispos; 2020 Jun; 48(6):481-490. PubMed ID: 32193358
[TBL] [Abstract][Full Text] [Related]
3. The effect of ketoconazole on praziquantel pharmacokinetics and the role of CYP3A4 in the formation of X-OH-praziquantel and not 4-OH-praziquantel.
Nleya L; Thelingwani R; Li XQ; Cavallin E; Isin E; Nhachi C; Masimirembwa C
Eur J Clin Pharmacol; 2019 Aug; 75(8):1077-1087. PubMed ID: 31089768
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and microsomal oxidation of praziquantel and its effects on the P450 system in three-month-old lambs infested by Fasciola hepatica.
Giorgi M; Salvatori AP; Soldani G; Giusiani M; Longo V; Gervasi PG; Mengozzi G
J Vet Pharmacol Ther; 2001 Aug; 24(4):251-9. PubMed ID: 11555180
[TBL] [Abstract][Full Text] [Related]
5. Metabolic profiling of praziquantel enantiomers.
Wang H; Fang ZZ; Zheng Y; Zhou K; Hu C; Krausz KW; Sun D; Idle JR; Gonzalez FJ
Biochem Pharmacol; 2014 Jul; 90(2):166-78. PubMed ID: 24821110
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and bioavailability of different praziquantel brands.
Botros S; El-Lakkany N; Seif el-Din SH; Sabra AN; Ibrahim M
Exp Parasitol; 2011 Feb; 127(2):515-21. PubMed ID: 21044626
[TBL] [Abstract][Full Text] [Related]
7. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
8. Biotransformation of praziquantel by human cytochrome p450 3A4 (CYP 3A4).
Godawska-Matysik A; Kieć-Kononowicz K
Acta Pol Pharm; 2006; 63(5):381-5. PubMed ID: 17357589
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic Study of Praziquantel Enantiomers and Its Main Metabolite R-trans-4-OH-PZQ in Plasma, Blood and Dried Blood Spots in Opisthorchis viverrini-Infected Patients.
Meister I; Kovac J; Duthaler U; Odermatt P; Huwyler J; Vanobberghen F; Sayasone S; Keiser J
PLoS Negl Trop Dis; 2016 May; 10(5):e0004700. PubMed ID: 27152952
[TBL] [Abstract][Full Text] [Related]
10. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes.
Margolis JM; O'Donnell JP; Mankowski DC; Ekins S; Obach RS
Drug Metab Dispos; 2000 Oct; 28(10):1187-91. PubMed ID: 10997938
[TBL] [Abstract][Full Text] [Related]
11. Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.
Chang Y; Fang WB; Lin SN; Moody DE
Basic Clin Pharmacol Toxicol; 2011 Jan; 108(1):55-62. PubMed ID: 20825389
[TBL] [Abstract][Full Text] [Related]
12. Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: Two Phase I Studies.
Bagchus WM; Bezuidenhout D; Harrison-Moench E; Kourany-Lefoll E; Wolna P; Yalkinoglu O
Clin Transl Sci; 2019 Jan; 12(1):66-76. PubMed ID: 30536632
[TBL] [Abstract][Full Text] [Related]
13. Clinically relevant enantiomer specific R- and S-praziquantel pharmacokinetic drug-drug interactions with efavirenz and ritonavir.
Mutiti CS; Kapungu NN; Kanji CR; Stadler N; Stingl J; Nhachi C; Hakim J; Masimirembwa C; Thelingwani RS
Pharmacol Res Perspect; 2021 May; 9(3):e00769. PubMed ID: 33929078
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.
Allqvist A; Miura J; Bertilsson L; Mirghani RA
Eur J Clin Pharmacol; 2007 Feb; 63(2):173-9. PubMed ID: 17200836
[TBL] [Abstract][Full Text] [Related]
15. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol.
Usmani KA; Hodgson E; Rose RL
Chem Biol Interact; 2004 Dec; 150(3):221-32. PubMed ID: 15560889
[TBL] [Abstract][Full Text] [Related]
16. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.
Yoshimoto K; Echizen H; Chiba K; Tani M; Ishizaki T
Br J Clin Pharmacol; 1995 Apr; 39(4):421-31. PubMed ID: 7640150
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the pharmacokinetic-pharmacodynamic relationship of praziquantel in the Schistosoma mansoni mouse model.
Abla N; Keiser J; Vargas M; Reimers N; Haas H; Spangenberg T
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005942. PubMed ID: 28934207
[TBL] [Abstract][Full Text] [Related]
18. CYP2C19 and CYP2J2 genotypes predict praziquantel plasma exposure among Ethiopian school-aged children.
Gebreyesus TD; Makonnen E; Telele NF; Barry A; Mnkugwe RH; Gerba H; Dahl ML; Aklillu E
Sci Rep; 2024 May; 14(1):11730. PubMed ID: 38778126
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms.
Shinde DD; Kim MJ; Jeong ES; Kim YW; Lee JW; Shin JG; Kim DH
J Toxicol Environ Health A; 2014; 77(22-24):1419-30. PubMed ID: 25343291
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective interaction between tetrahydropalmatine enantiomers and CYP enzymes in human liver microsomes.
Sun SY; Wang YQ; Li LP; Wang L; Zeng S; Zhou H; Jiang HD
Chirality; 2013 Jan; 25(1):43-7. PubMed ID: 23001793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
